Macrolide antibiotic that acts as a specific inhibitor of vacuolar-type H+-ATPase.
Product Details
| Formula: | C44H65NO13 |
| |
| MW: | 816.0 |
| |
| Source: | Isolated from Streptomyces griseus. |
| |
| CAS: | 88899-56-3; 80112-34-1 |
| |
| Purity: | ≥95% (HPLC) |
| |
| Identity: | Determined by 1H-NMR. |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Slightly soluble in methanol or DMSO; insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light when in solution. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
V-ATPase Blockade Reduces Renal Gluconeogenesis and Improves Insulin Secretion in Type 2 Diabetic Rats: J. Hirao, et al.; Hypertens. Res.
43, 1079 (2020),
Abstract;
Full Text
Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma: V.K. Emruli, et al.; BMC Cancer
16, 493 (2016),
Abstract;
Full Text
Autophagy, bafilomycin and cell death: the "a-B-cs" of plecomacrolide-induced neuroprotection: J.J. Shacka, et al.; Autophagy
2, 228 (2006),
Abstract;
Biosynthetic investigations of the V-type ATPase inhibitors bafilomycin A1, B1 and concanamycin A: T. Schuhmann and S. Grond; J. Antibiot. (Tokyo)
57, 655 (2004),
Abstract;
Bafilomycins and concanamycins as inhibitors of V-ATPases and P-ATPases: S. Drose and K. Altendorf; J. Exp. Biol.
200, 1 (1997),
Abstract;
Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity: G. Werner, et al.; J. Antibiot. (Tokyo)
37, 110 (1984),
Abstract;
